Evolution of HER2-low expression from primary to recurrent breast cancer

About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC sample...

Descripción completa

Detalles Bibliográficos
Autores principales: Miglietta, Federica, Griguolo, Gaia, Bottosso, Michele, Giarratano, Tommaso, Lo Mele, Marcello, Fassan, Matteo, Cacciatore, Matilde, Genovesi, Elisa, De Bartolo, Debora, Vernaci, Grazia, Amato, Ottavia, Conte, PierFranco, Guarneri, Valentina, Dieci, Maria Vittoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511010/
https://www.ncbi.nlm.nih.gov/pubmed/34642348
http://dx.doi.org/10.1038/s41523-021-00343-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511010/
https://www.ncbi.nlm.nih.gov/pubmed/34642348
http://dx.doi.org/10.1038/s41523-021-00343-4

Ejemplares similares